Telomir Pharmaceuticals, Common Stock Performance
| TELO Stock | 4.91 0.03 0.61% |
The entity has a beta of 2.08, which indicates a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Telomir Pharmaceuticals, will likely underperform. At this point, Telomir Pharmaceuticals, has a negative expected return of -0.2%. Please make sure to validate Telomir Pharmaceuticals,'s jensen alpha, skewness, as well as the relationship between the Skewness and day median price , to decide if Telomir Pharmaceuticals, performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Telomir Pharmaceuticals, Common has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of uncertain performance in the last few months, the Stock's essential indicators remain very healthy which may send shares a bit higher in January 2025. The recent disarray may also be a sign of long period up-swing for the firm investors. ...more
Actual Historical Performance (%)
One Day Return (0.61) | Five Day Return (8.40) | Year To Date Return (29.86) | Ten Year Return 12.2 K | All Time Return 12.2 K |
1 | Telomir Pharmaceuticals, Inc.s last weeks 12 percent decline must have disappointed retail investors who have a significant stake | 10/01/2024 |
2 | Disposition of 100000 shares by Bay Shore Trust of Telomir Pharmaceuticals, at 3.73 subject to Rule 16b-3 | 11/21/2024 |
3 | TELO Test Results Continue to Excite | 12/03/2024 |
4 | Telomir Pharmaceuticals enters into stock purchase agreement | 12/11/2024 |
5 | Telomir Pharmaceuticals Secures 1 Million At 7 Per Share In No-Warrant, Restricted Stock Deal, Underscoring Investor Confidence With A 20 percent Premium Valuat... | 12/16/2024 |
| Begin Period Cash Flow | 1419.00 |
Telomir |
Telomir Pharmaceuticals, Relative Risk vs. Return Landscape
If you would invest 670.00 in Telomir Pharmaceuticals, Common on September 19, 2024 and sell it today you would lose (179.00) from holding Telomir Pharmaceuticals, Common or give up 26.72% of portfolio value over 90 days. Telomir Pharmaceuticals, Common is currently does not generate positive expected returns and assumes 7.9018% risk (volatility on return distribution) over the 90 days horizon. In different words, 70% of stocks are less volatile than Telomir, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Telomir Pharmaceuticals, Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Telomir Pharmaceuticals,'s investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Telomir Pharmaceuticals, Common, and traders can use it to determine the average amount a Telomir Pharmaceuticals,'s price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0259
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | TELO |
Estimated Market Risk
| 7.9 actual daily | 70 70% of assets are less volatile |
Expected Return
| -0.2 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.03 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Telomir Pharmaceuticals, is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Telomir Pharmaceuticals, by adding Telomir Pharmaceuticals, to a well-diversified portfolio.
Telomir Pharmaceuticals, Fundamentals Growth
Telomir Stock prices reflect investors' perceptions of the future prospects and financial health of Telomir Pharmaceuticals,, and Telomir Pharmaceuticals, fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Telomir Stock performance.
| Return On Equity | -17.53 | ||||
| Return On Asset | -2.05 | ||||
| Current Valuation | 147.08 M | ||||
| Shares Outstanding | 29.75 M | ||||
| Price To Book | 332.47 X | ||||
| EBITDA | (11.43 M) | ||||
| Net Income | (13.07 M) | ||||
| Total Debt | 101 K | ||||
| Book Value Per Share | 0.01 X | ||||
| Cash Flow From Operations | (3.86 M) | ||||
| Earnings Per Share | (0.78) X | ||||
| Market Capitalization | 146.98 M | ||||
| Total Asset | 4.77 M | ||||
| Retained Earnings | (14.06 M) | ||||
| Working Capital | (900.34 K) | ||||
About Telomir Pharmaceuticals, Performance
By examining Telomir Pharmaceuticals,'s fundamental ratios, stakeholders can obtain critical insights into Telomir Pharmaceuticals,'s financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Telomir Pharmaceuticals, is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (2.74) | (2.88) | |
| Return On Capital Employed | (1.15) | (1.09) | |
| Return On Assets | (2.74) | (2.88) | |
| Return On Equity | (3.80) | (3.61) |
Things to note about Telomir Pharmaceuticals, performance evaluation
Checking the ongoing alerts about Telomir Pharmaceuticals, for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Telomir Pharmaceuticals, help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Telomir Pharmaceuticals, generated a negative expected return over the last 90 days | |
| Telomir Pharmaceuticals, has high historical volatility and very poor performance | |
| Telomir Pharmaceuticals, has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (13.07 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Telomir Pharmaceuticals, generates negative cash flow from operations | |
| Telomir Pharmaceuticals, has a poor financial position based on the latest SEC disclosures | |
| About 43.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from benzinga.com: Telomir Pharmaceuticals Secures 1 Million At 7 Per Share In No-Warrant, Restricted Stock Deal, Underscoring Investor Confidence With A 20 percent Premium Valuation |
- Analyzing Telomir Pharmaceuticals,'s financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Telomir Pharmaceuticals,'s stock is overvalued or undervalued compared to its peers.
- Examining Telomir Pharmaceuticals,'s industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Telomir Pharmaceuticals,'s management team can have a significant impact on its success or failure. Reviewing the track record and experience of Telomir Pharmaceuticals,'s management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Telomir Pharmaceuticals,'s stock. These opinions can provide insight into Telomir Pharmaceuticals,'s potential for growth and whether the stock is currently undervalued or overvalued.
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Telomir Pharmaceuticals, Common. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Crypto Correlations module to use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Telomir Pharmaceuticals,. If investors know Telomir will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Telomir Pharmaceuticals, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.78) | Return On Assets (2.05) | Return On Equity (17.53) |
The market value of Telomir Pharmaceuticals, is measured differently than its book value, which is the value of Telomir that is recorded on the company's balance sheet. Investors also form their own opinion of Telomir Pharmaceuticals,'s value that differs from its market value or its book value, called intrinsic value, which is Telomir Pharmaceuticals,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Telomir Pharmaceuticals,'s market value can be influenced by many factors that don't directly affect Telomir Pharmaceuticals,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Telomir Pharmaceuticals,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if Telomir Pharmaceuticals, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Telomir Pharmaceuticals,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.